Glutathione Reductase Underlies the Stability of Mutant P53 by Antagonizing Protein Glutathionylation

Overview

Journal Redox Biol

Specialties Biology
Cell Biology
Endocrinology

Date 2025 Feb 21

PMID 39983342

Authors

Liansheng Wang

Suqin Zhong

Xinru Fan

Yuxue Xu

Meimei Wang

Youcui Xu

Yuanyuan Cai

Zhong Cao

Zhiming Ye

Longping Wen

Pengfei Wei

Affiliations

Soon will be listed here.

Abstract

Mutp53 level is widely variable among individual cancer cells in tumor tissues, and within cells a higher level of mutp53 is usually observed in the nucleus as compared to the cytoplasm. This spatial heterogeneity in mutp53 expression has been well documented and likely plays an important role in tumor therapeutic resistance. However, its underlying mechanism remains poorly understood. In this study, we first revealed a critical role of micro-environmental reducing status in regulating mutp53 stability and spatially heterogeneous accumulation. Immunofluorescence and ThiolTracker Violet dye staining demonstrated a clear correlation between the cellular mutp53 level and the reducibility in the patient-derived tumor tissues and mutp53-expressing cancer cell lines. The nucleus exhibited both higher reducibility and more mutp53 accumulation than the cytoplasm did. Supplementing GSH exacerbated the accumulation of mutp53, while consuming GSH led to extensive depletion of mutp53, suggesting that the environmental reducing status kept mutp53 stability. Mechanistically, S-glutathionylation could trigger ubiquitination and proteasomal degradation of mutp53. A highly-reducing local environment preserved mutp53 stability by inhibiting glutathionylation and subsequent proteasomal degradation of mutp53, which also provided an explanation for the differential accumulation of mutp53 proteins in the nucleus and cytoplasm. Thirdly, we revealed that the expression level of glutathione reductase (GR) was positively correlated with mutp53 accumulation across the cultured mutp53-expressing cell lines, patient-derived tumor tissues and patient databases. Over-expression of GR reinforced the environmental reducibility, affected glutathionylation and improved mutp53 accumulation, while inhibiting GR either by chemical inhibitors or genetic approach induced massive clearance of a variety of mutp53 and effectively retarded the growth of p53-mutated cell-derived xenografts in mice. These studies provided an explanation for the widely-observed spatial heterogeneous accumulation of mutp53 proteins, and inhibiting GR or directly consuming GSH represented a promising strategy for mutp53 carrying cancer therapy.

References

Takeshita K, Kawaguchi K, Fujii-Aikawa K, Ueno M, Okazaki S, Ono M . Heterogeneity of regional redox status and relation of the redox status to oxygenation in a tumor model, evaluated using electron paramagnetic resonance imaging. Cancer Res. 2010; 70(10):4133-40. PMC: 7366877. DOI: 10.1158/0008-5472.CAN-09-4369. View

Cheteh E, Augsten M, Rundqvist H, Bianchi J, Sarne V, Egevad L . Human cancer-associated fibroblasts enhance glutathione levels and antagonize drug-induced prostate cancer cell death. Cell Death Dis. 2017; 8(6):e2848. PMC: 5520886. DOI: 10.1038/cddis.2017.225. View

Zhou X, Hao Q, Lu H . Mutant p53 in cancer therapy-the barrier or the path. J Mol Cell Biol. 2018; 11(4):293-305. PMC: 6487791. DOI: 10.1093/jmcb/mjy072. View

Alexandrova E, Yallowitz A, Li D, Xu S, Schulz R, Proia D . Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment. Nature. 2015; 523(7560):352-6. PMC: 4506213. DOI: 10.1038/nature14430. View

Grek C, Zhang J, Manevich Y, Townsend D, Tew K . Causes and consequences of cysteine S-glutathionylation. J Biol Chem. 2013; 288(37):26497-504. PMC: 3772197. DOI: 10.1074/jbc.R113.461368. View

Butturini E, Darra E, Chiavegato G, Cellini B, Cozzolino F, Monti M . S-Glutathionylation at Cys328 and Cys542 impairs STAT3 phosphorylation. ACS Chem Biol. 2014; 9(8):1885-93. DOI: 10.1021/cb500407d. View

Marusyk A, Janiszewska M, Polyak K . Intratumor Heterogeneity: The Rosetta Stone of Therapy Resistance. Cancer Cell. 2020; 37(4):471-484. PMC: 7181408. DOI: 10.1016/j.ccell.2020.03.007. View

Zhang J, Ye Z, Singh S, Townsend D, Tew K . An evolving understanding of the S-glutathionylation cycle in pathways of redox regulation. Free Radic Biol Med. 2018; 120:204-216. PMC: 5940525. DOI: 10.1016/j.freeradbiomed.2018.03.038. View

Ingallina E, Sorrentino G, Bertolio R, Lisek K, Zannini A, Azzolin L . Mechanical cues control mutant p53 stability through a mevalonate-RhoA axis. Nat Cell Biol. 2017; 20(1):28-35. PMC: 6179142. DOI: 10.1038/s41556-017-0009-8. View

10.

Cook J, Pass H, Iype S, Friedman N, DeGraff W, Russo A . Cellular glutathione and thiol measurements from surgically resected human lung tumor and normal lung tissue. Cancer Res. 1991; 51(16):4287-94. View

11.

Yuan Y . Spatial Heterogeneity in the Tumor Microenvironment. Cold Spring Harb Perspect Med. 2016; 6(8). PMC: 4968167. DOI: 10.1101/cshperspect.a026583. View

12.

Wang W, Kryczek I, Dostal L, Lin H, Tan L, Zhao L . Effector T Cells Abrogate Stroma-Mediated Chemoresistance in Ovarian Cancer. Cell. 2016; 165(5):1092-1105. PMC: 4874853. DOI: 10.1016/j.cell.2016.04.009. View

13.

Choi S, Chen M, Cryns V, Anderson R . A nuclear phosphoinositide kinase complex regulates p53. Nat Cell Biol. 2019; 21(4):462-475. PMC: 7017954. DOI: 10.1038/s41556-019-0297-2. View

14.

Palmen N, Evelo C . Glutathione depletion in human erythrocytes and rat liver: a study on the interplay between bioactivation and inactivation functions of liver and blood. Toxicol In Vitro. 2010; 10(3):273-81. DOI: 10.1016/0887-2333(96)00002-1. View

15.

Sun X, Guo C, Huang C, Lv N, Chen H, Huang H . GSTP alleviates acute lung injury by S-glutathionylation of KEAP1 and subsequent activation of NRF2 pathway. Redox Biol. 2024; 71:103116. PMC: 10945259. DOI: 10.1016/j.redox.2024.103116. View

16.

Egeblad M, Nakasone E, Werb Z . Tumors as organs: complex tissues that interface with the entire organism. Dev Cell. 2010; 18(6):884-901. PMC: 2905377. DOI: 10.1016/j.devcel.2010.05.012. View

17.

Kennedy L, Sandhu J, Harper M, Cuperlovic-Culf M . Role of Glutathione in Cancer: From Mechanisms to Therapies. Biomolecules. 2020; 10(10). PMC: 7600400. DOI: 10.3390/biom10101429. View

18.

Wang M, Yang Z, Song Y, Wei P, Ishiwme N, Wang L . Proteasomal and autophagy-mediated degradation of mutp53 proteins through mitochondria-targeting aggregation-induced-emission materials. Acta Biomater. 2022; 150:402-412. DOI: 10.1016/j.actbio.2022.07.057. View

19.

Sun J, Zhou C, Zhao Y, Zhang X, Chen W, Zhou Q . Quiescin sulfhydryl oxidase 1 promotes sorafenib-induced ferroptosis in hepatocellular carcinoma by driving EGFR endosomal trafficking and inhibiting NRF2 activation. Redox Biol. 2021; 41:101942. PMC: 8024711. DOI: 10.1016/j.redox.2021.101942. View

20.

Niu B, Liao K, Zhou Y, Wen T, Quan G, Pan X . Application of glutathione depletion in cancer therapy: Enhanced ROS-based therapy, ferroptosis, and chemotherapy. Biomaterials. 2021; 277:121110. DOI: 10.1016/j.biomaterials.2021.121110. View